59.6% of Gilenya patients achieve NEDA in study
59.6% of Gilenya patients achieve NEDA in study
Novartis has announced the results of a phase IV multiple sclerosis (MS) clinical outcomes and MRI study in the US. It confirmed the effectiveness of Gilenya (fingolimod) in a real-world setting, supporting previous findings from phase III trials...Read more - http://www.ms-uk.org/75-gilenya-patient ... udy-040517
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 5 Replies
- 14768 Views
-
Last post by gibbledygook
-
- 0 Replies
- 1546 Views
-
Last post by frodo
-
- 0 Replies
- 1549 Views
-
Last post by NHE
-
- 0 Replies
- 2470 Views
-
Last post by frodo
-
- 0 Replies
- 2286 Views
-
Last post by DIM
-
- 0 Replies
- 1654 Views
-
Last post by frodo
-
- 0 Replies
- 2021 Views
-
Last post by DIM
-
- 0 Replies
- 1987 Views
-
Last post by Tif